Dynavax Announces February 15, 2005 Webcast of Fourth Quarter and Year-End 2004 Financial Results and Outlook

February 7, 2005 at 12:00 AM EST
Dynavax Announces February 15, 2005 Webcast of Fourth Quarter and Year-End 2004 Financial Results and Outlook

BERKELEY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) will announce it's 2004 fourth quarter and year-end financial results on Tuesday February 15, 2005.

The announcement will be followed by a live webcast at 5:00 p.m. EST of a discussion by Dynavax Technologies management of fourth quarter and year-end 2004 financial results and 2005 outlook.

The webcast can be accessed on Dynavax Technologies' website at http://www.dynavax.com . The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

An audio replay of the webcast will be available until February 22, 2005 by dialing 888-286-8010; conference identification number 12744711. International callers can dial 617-801-6888; conference identification number 12744711.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three initial indications: ragweed allergy immunotherapeutic, currently in a Phase 2/3 clinical trial; a Hepatitis B vaccine, currently in a Phase 2/3 clinical trial; and an asthma immunotherapeutic that has completed a Phase 2 exploratory trial.

SOURCE Dynavax Technologies

CONTACT: Jane M. Green, Ph.D., Vice President, Corporate Communications of Dynavax Technologies, +1-510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com
02/07/2005 17:53 EST http://www.prnewswire.com